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symptom levels of anxiety and depression, and sleep impairment
among patients with NeP. METHODS: Participants in an obser-
vational, prospective and multicentre study in Spain (DONEGA
study) with NeP of different etiologies, completed the Short
Form-McGill Pain Questionnaire (SF-MPQ), the Mini Mental
State Examination (MMSE), the COVI Anxiety Scale, the
RASKIN Depression Rating Scale, and the MOS Sleep Scale
(MOS-S) at baseline. RESULTS: A total of 1519 patients above
18 years [mean ± SD; 56.0 ± 13.7 years old (58.8% female)] with
NeP were enrolled in the study. Peripheral NeP was presented in
>95.0% subjects. Patients had NeP for 1.1 ± 2.8 years, and
83.3% were on any type of analgesic treatment at baseline: oral
analgesics (51.2%), topical analgesics (26.9%), NSAID’s
(11.1%), antiepileptics (7.3%), and psychoanaleptics (3.5%).
Average Pain scores were 13.1 ± 8.2pts, 10.0 ± 5.8pts, and 3.1
± 3.3pts, for total scale (range 0–45), sensory domain (range
0–33), and affective domain (range 0–12), respectively. Present
pain intensity was 2.8 ± 1.0 (range 0–5) and mean pain past week
on a VAS scale was 71,2 ± 18,9mm. Pain slightly interfered with
patient mental functioning (average MMSE score; 27.2 ± 3.6pts,
18.0% of patients with MMSE score £ 24pts). Pain interfered
with all sleep attributes, obtaining high scoring in composite
measures; SLP6; 45.3 ± 21.8, and SLP9; 46.8 ± 21.1. The 24.4%
and 15.6% of patients had moderate to severe symptoms levels
of anxiety and depression (RASKIN and COVI scores ≥ 9 on
3–15 scale), with an average depression and anxiety scores of
6.3 ± 3.3pts and 5.4 ± 2.8, respectively. CONCLUSIONS: NeP
decreases patient mental functioning as assessed by MMSE,
while increasing anxiety and depression symptoms and sleep
problems. These ﬁndings substantially deteriorated with pain
severity.
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OBJECTIVES: Utilities for Parkinson’s Disease (PD) are needed
for cost-utility analyses of antiparkinsonian treatments but are
not always available from PD studies. We compared the perfor-
mance of classiﬁcation and regression tree (CART) analysis with
multiple regression for mapping the Uniﬁed Parkinson’s Disease
Rating Scale (UPDRS) to utilities. METHODS: We used data
from an ongoing prospective cost study of the German Compe-
tence Network for Parkinson Syndromes. Single UPDRS items
were used as predictors for utilities assessed with EuroQoL (EQ-
5D). First, we developed a multiple regression model using
forward selection based on likelihood ratio testing (p < 0.05).
Second, we developed a CART model using t-test statistics as
selection criteria and adjusting p-values for non-dichotomous
variables by the Miller & Siegmund method. The resulting
mutual exclusive and exhausting groups were used as predictors
in a multiple linear regression model. The performance (good-
ness-of-ﬁt) of both approaches was compared using explained
variance (adjusted R-square statistic). RESULTS: The ﬁnal mul-
tiple regression model included a linear combination of three
UPDRS subscore variables (i.e., parts II–IV) and yielded an
adjusted R-square of 0.55. The ﬁnal CART model had three
levels with four variables partitioning the sample into ﬁve sub-
groups. These variables were level of rigidity (UPDRS item 22),
problems arising from a chair (item 27), posture (item 28), and
unpredictable ﬂuctuations (item 36). The mean (median) utility
in the 5 subgroups was 0.90 (0.89), 0.81 (0.89), 0.68 (0.70),
0.66 (0.70), and 0.32 (0.29). The CART model had adjusted R-
square of 0.50. CONCLUSIONS: Multiple regression performed
slightly better than CART when used to predict utilities based
on clinical characteristics of PD patients. Both models were
based on feasible and parsimonious prediction rules with only
three and four variables, respectively. Whereas multiple regres-
sion modeling is the more widely used statistical approach,
CART-based prediction models may be easier to interpret for
physicians.
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OBJECTIVES: We have recently reported on a generic, multi-
outcome disease model for Parkinson’s disease (PD). Now we
present ﬁrst results of internal, external and cross-model valida-
tion. METHODS: Our lifetime PD Markov model simulates a
hypothetical cohort of patients moving through health states
reﬂecting patient characteristics that would be observed in the
absence of treatment (Hoehn&Yahr “off” states [HYoff]). We
used HYoff I-V and death as Markov states. The model is
designed to simultaneously predict multiple outcomes, e.g. time
in Hoehn&Yahr “on” states (HYon) observed under treatment,
quality-adjusted life expectancy (QALE), or complication rates.
As internal validation, we compared time in HYoff stages pre-
dicted by our model to results reported in the progression study
used to derive our input parameters. As external validation, we
compared model results of mean times in HYoff and HYon states
with extern literature data not used in our model. Finally, we
cross-validated our model comparing QALE under levodopa
treatment with QALE of other published models reporting this
outcome. RESULTS: Internal validation of HYoff input data
showed a 97.4–99.9% accuracy. Although external validation of
average HYoff progression rates overestimated external popula-
tion data from Hoehn & Yahr (1967) by 19%, the mean HYon
progression rate predicted by our model (0.42 HY stages/y)
matched well with estimates reported in the literature (0.40 HY
stages/y). After restricting our model to a 5-year time horizon,
discounted QALYs exceeded those from 2 other published
models by 24% and 35%. This differences were mostly attrib-
utable to different Markov state-speciﬁc utilities. As other
Markov models for drug treatment did not evaluate QALE, we
could not cross-validate for this outcome. CONCLUSIONS: Our
PD model is internal valid and closely reproduces external data
for progression under standard treatment. Variability in QALE
are due to a combination of different model design, state-speciﬁc
utilities, and underlying study populations.
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